This site is intended only for healthcare professionals resident in the Republic of Ireland




Sign in or RegisterLog out Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up



AboutEfficacySafetyDosingSupport & ResourcesPatient SupportMaterialsVideos

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Refer to section 4.8 of the SmPC for how to report adverse reactions.

Brought to you by Pfizer—a company committed to the pediatric growth hormone (GH) community1

For decades, Pfizer has been dedicated to supporting and improving the lives of patients with growth hormone disorders.

See how NGENLA enables once-weekly dosing

NGENLA is a long-acting protein known as a recombinant human growth hormone (rhGH), obtained through recombinant DNA technology. It contains 3 copies of naturally occurring C-terminal peptides (CTPs) to extend half-life.2

  • The CTPs in NGENLA are naturally occurring peptides derived from the beta chain of human chorionic gonadotropin (hCG)2,3
  • The CTP of hCG contributes to longer serum half-life and has no effect on the interaction of the molecule with its receptor2,3
Learn about the NGENLA mechanism of action2,3 Consider NGENLA for all your appropriate patients from age 3 years with paediatric growth hormone deficiency2

Ngenla▼ Prescribing Information

References:Ranke MB, Price DA, Reiter EO (eds): Growth Hormone Therapy in Pediatrics - 20 Years of KIGS. Basel, Karger, 2007, pp 1-5. doi:10.1159/000101492NGENLA® Summary of Product Characteristics.Calo D, Hart G, Hoffman M, et al. Enhancing the longevity and in vivo potency of therapeutic proteins: the power of CTP. Precis Med. 2015;2:e989. doi:10.14800/pm.989

Access data on the efficacy of NGENLA.

View efficacy data

Learn more about clinical safety data of NGENLA in children with GH deficiency.

View safety data

Click here for more information on NGENLA once weekly dosing and administration.

See instructions

Legal Category: S1A
Further information is available upon request

PP-NGE-IRL-0015 Date of Preparation Dec 2022

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.


Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.